IL3RA and acute myeloid leukemia: Because of the overexpression on AML blasts and LSCs, CD123 has been considered as a target in AML, and agents that specifically interact with this receptor have been developed, such as bispecific antibodies, antibody-drug conjugates or naked antibodies (Pelosi et al., 2023).